Research synthesisLow evidenceModerate effect3 studies · 3 beneficial · 0 neutral · 0 harmful
Across 3 randomized controlled trials, Lactobacillus gasseri BNR17 showed moderate beneficial effects on reducing abdominal pain in populations with functional constipation or irritable bowel syndrome (IBS). All 3 studies reported statistically significant improvements, with effect sizes ranging from moderate to large. Doses and study durations were not consistently reported, limiting precise dose-response conclusions.
- Studied populations: women with functional constipation, patients with diarrhea-dominant IBS, volunteers with IBS and BMI over 23 kg/m²
Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Study durations were not consistently reported, and dosing information was incomplete, making it difficult to generalize optimal use.
Generated May 12, 2026